In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. 11542-11542
Abstract:
11542 Background: The soluble form Programmed Death-Ligand 1(sPDL1) is suggested to have immunosuppressive activity and under investigation as candidate biomarker for immuno-oncology drug development. In this study, we measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its prognostic implication and dynamics during chemotherapy in biliary tract cancer (BTC) patients. Methods: From 90 advanced BTC patients (training cohort 42 patients, validation cohort 48 patients) who were candidates for palliative 1 st -line chemotherapy, blood was collected at pre-and post-chemotherapy. sPDL1 was measured using an enzyme-linked immunosorbent assay. Response to chemotherapy, overall survival (OS) and other prognostic factors including neutrophil-lymphocyte ratio (NLR) were also obtained. Results: OS of all patients was 11.5 months (95% CI; 9.7-16.2). The best response was CR in 7 patients (7.8%), PR 20 patients (22.2%), SD 52 patients (57.8%) and PD 11 patients (12.2%). Median sPDL1 at pre-chemotherapy was 0.97 ng/mL (range 0.6-1.9). Patients with high pre-chemo sPDL1 (≥ 1.30 ng/mL) showed worse OS than patients with low pre-chemo sPDL1 (9.1 vs. 12.5 months, p =0.003). In multivariate analysis, high pre-chemo sPDL1 (HR 1.96, 95% CI; 1.2-3.9, p = 0.011) and pre-chemo NLR (HR 1.82, 95% CI; 1.1-3.0, p = 0.020) were independent poor prognostic factors for OS. Post-chemotherapy sPDL1 and its changes compared with pre-chemotherapy were not significantly different across tumor response groups. However, at the time of disease progression, sPDL1 was increased significantly compared with pre-chemo sPDL1 (1.59 ng/mL vs 0.72 ng/mL, p = 0.003). In PR group, sPDL1 at pre-chemo, post-chemo, and PD was 1.19, 0.98, and 2.77 ng/mL, respectively. In SD group, sPDL1 at pre-chemo, post-chemo, and PD was 1.16, 1.19, and 1.83 ng/mL, respectively. In PD group, sPDL1 at pre-chemo and PD was 0.62, and 1.04 ng/mL. Conclusions: sPDL1 at pre-chemotherapy confers the prognostic value for OS in BTC patients under palliative chemotherapy. The dynamics of sPDL1 during chemotherapy correlates with disease progression.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.15_suppl.11542
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
Bookmarklink